StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross jointly filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 730,223 shares of CalciMedica, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each reporting person is reported as beneficially owning 730,223 shares of CalciMedica common stock, par value $0.00001 per share.
  • Percent of class: The 730,223 shares represent 9.99% of CalciMedica's common stock, with cover pages listing the figure as 9.9% due to EDGAR field limitations.
  • Composition of holdings: The 730,223 shares consist of 248,972 shares of common stock, 248,972 shares underlying Series A Warrants, and 232,279 shares underlying Series B Warrants.
  • Excluded shares: An additional 16,693 shares underlying Series B Warrants are excluded from the reported total due to the 9.99% beneficial ownership limitation.
  • Shared voting and dispositive power: All 730,223 shares are held with shared voting and shared dispositive power; sole voting and sole dispositive power are each reported as zero.
  • Triggering event date: The date of the event requiring the filing is reported as September 30, 2026.
  • Reverse stock split: Share amounts in the percent-of-class calculation are adjusted to reflect a 1-for-5 reverse stock split of CalciMedica common stock that became effective August 27, 2026.

StemPoint Capital and Michelle Ross Report Joint Stake in CalciMedica

According to the Schedule 13G filing, StemPoint Capital LP (a Delaware limited partnership), StemPoint Capital Management GP LLC (a Delaware limited liability company), and Michelle Ross (a U.S. citizen) are the three reporting persons, each sharing the same business address at 520 Madison Avenue, 19th Floor, New York, NY 10022. The filing states that each reporting person may be deemed the beneficial owner of 730,223 shares of CalciMedica, Inc. (NASDAQ:CALC) common stock. StemPoint Capital LP is classified as an investment adviser and limited partnership, StemPoint Capital Management GP LLC as a limited liability company, and Michelle Ross as a holding company and individual.

The filing discloses that the 730,223 shares are composed of 248,972 shares of common stock held directly, 248,972 shares issuable upon exercise of Series A Warrants, and 232,279 shares issuable upon exercise of Series B Warrants. The Series A and B Warrants are each subject to a 9.99% beneficial ownership limitation. The percent-of-class figure of 9.99% is calculated using 6,828,292 shares reported as issued and outstanding as of August 5, 2026, in CalciMedica's Form 10-Q filed August 6, 2026, adjusted for the 1-for-5 reverse stock split effective August 27, 2026, plus the warrant shares added in accordance with Rule 13d-3(d)(1)(i). The filing notes that 16,693 additional shares underlying Series B Warrants are excluded from the aggregate total because of the beneficial ownership limitation.

The filing certifies, as required, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The statement was signed by Sean C. Tan as authorized signatory for both StemPoint entities and by Michelle Ross individually, all dated November 16, 2026.

What Was Disclosed

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross filed a joint Schedule 13G disclosing aggregate beneficial ownership of 730,223 shares, or 9.99%, of CalciMedica, Inc. common stock as of September 30, 2026, including shares underlying Series A and Series B Warrants.